Hospira recalls mount as key plant flounders

Hospira ($HSP) is recalling yet another product as it struggles to bring its key injectables plant up to FDA snuff. It's at least the fourth time this year that Hospira has recalled a drug. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.